Most patients with Alzheimer's disease present with amnestic problems; however, a
substantial proportion, over-represented in young-onset cases, have atypical phenotypes …

Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …

Neurodegenerative diseases are the most common cause of dementia. Although their
underlying molecular pathologies have been identified, there is substantial heterogeneity in …

Many human brain disorders are associated with characteristic alterations in the structural
and functional connectivity of the brain. In this article, we explore how commonalities and …

Tau is a hallmark pathology of Alzheimer's disease, and animal models have suggested that
tau spreads from cell to cell through neuronal connections, facilitated by β-amyloid (A β). We …

The accumulation of pathological misfolded tau is a feature common to a collective of
neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is …

In Alzheimer's diseases (AD), tau pathology is strongly associated with cognitive decline.
Preclinical evidence suggests that tau spreads across connected neurons in an activity …

Abstract See Hansson and Mormino (doi: 10.1093/brain/awy065) for a scientific commentary
on this article. Our objective was to compare different whole-brain and region-specific …

Advances in molecular positron emission tomography (PET) have enabled anatomic
tracking of brain pathology in longitudinal studies of normal aging and dementia, including …

Brain aging is accompanied by patterns of functional and structural change. Alzheimer's
disease (AD), a representative neurodegenerative disease, has been linked to accelerated …